Immunovant Inc [IMVT] stock is trading at $32.52, up 3.47%. An important factor to consider is whether the stock is rising or falling in short-term value. The IMVT shares have gain 3.01% over the last week, with a monthly amount drifted -15.22%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 12, March 2024, Immunovant Awarded U.S. Patent for IMVT-1402. In a post published today on Yahoo Finance, Composition of matter patent issued with coverage until June 2043.
From an analyst’s perspective:
Immunovant Inc [NASDAQ: IMVT] stock has seen the most recent analyst activity on March 13, 2024, when Goldman initiated its Buy rating and assigned the stock a price target of $50. Previously, JP Morgan started tracking the stock with Overweight rating on February 20, 2024, and set its price target to $51. On February 15, 2024, Wolfe Research initiated with a Outperform rating and assigned a price target of $55 on the stock. Deutsche Bank started tracking the stock assigning a Buy rating and suggested a price target of $50 on December 12, 2023. UBS upgraded its rating to a Buy and raised its price target to $55 on October 13, 2023. Raymond James upgraded its rating to Outperform for this stock on September 26, 2023, but kept the price target unchanged to $40. In a note dated May 01, 2023, BofA Securities initiated an Buy rating and provided a target price of $26 on this stock.
Immunovant Inc [IMVT] stock has fluctuated between $14.05 and $45.58 over the past year. Currently, Wall Street analysts expect the stock to reach $27.5 within the next 12 months. Immunovant Inc [NASDAQ: IMVT] shares were valued at $32.52 at the most recent close of the market. An investor can expect a potential drop of -15.44% based on the average IMVT price forecast.
Analyzing the IMVT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.61 and Total Capital is -0.37. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 31.49 points at the first support level, and at 30.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 33.34, and for the 2nd resistance point, it is at 34.16.
Immunovant Inc [IMVT] reported earnings per share of -$0.36 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.43/share, meaning a difference of $0.07 and a surprise factor of 16.30%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.45 per share as compared to estimates of -$0.47 per share, a difference of $0.02 representing a surprise of 4.30%.
Ratios To Look Out For
For context, Immunovant Inc’s Current Ratio is 22.14. On the other hand, the Quick Ratio is 22.14, and the Cash Ratio is 21.52.
Transactions by insiders
Recent insider trading involved Salzmann Peter, Chief Executive Officer, that happened on Feb 22 ’24 when 13454.0 shares were sold. Chief Financial Officer, Barnett Eva Renee completed a deal on Feb 22 ’24 to sell 2930.0 shares. Meanwhile, Chief Medical Officer Macias William L. sold 2221.0 shares on Feb 22 ’24.
